Actio Biosciences
Actio Biosciences works on 1 rare disease tracked on Trial Friend, including KCNT1-Related Epilepsy, with 3 recruiting clinical trials.
Actio Biosciences develops precision medicines for rare genetic disorders by translating genetic insights into small molecule treatments. The company focuses on rare genetic epilepsies and other neurological disorders, with its lead program ABS-1230 targeting KCNT1-associated seizure disorders.
Focus areas at Actio Biosciences
As a rare disease specialist, Actio Biosciences has active clinical trial programs and drug development efforts across 1 rare diseases, including KCNT1-Related Epilepsy. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows all active and recruiting studies sponsored by Actio Biosciences, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Actio Biosciences is headquartered in San Francisco, United States. The company dedicates its research and development resources exclusively to rare and orphan diseases, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Actio Biosciences Drug Pipeline
Actio Biosciences has 3 active clinical trials across 3 development stages, with 3 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline includes all of Actio Biosciences's active interventional trials, not only those targeting rare diseases. We show the full pipeline because a company's broader research activity, therapeutic expertise, and development infrastructure directly shape its ability to advance rare disease programs. A strong overall pipeline often signals deeper clinical operations, faster enrollment capabilities, and greater commitment to bringing new treatments to patients.
Actio Biosciences Clinical Trials (3)
Active and recruiting clinical trials sponsored by Actio Biosciences, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
FDA-Approved Drugs
Actio Biosciences Trial Locations
Actio Biosciences clinical trials are running at 3 sites in 2 countries. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Rare Disease Focus Areas (1)
Diseases targeted by Actio Biosciences's clinical trial and drug development programs
Patient Resources
Organizations and resources related to Actio Biosciences's rare disease focus areas
Frequently Asked Questions About Actio Biosciences
Common questions about Actio Biosciences's rare disease programs, clinical trials, and treatments.